Dong-A Socio Holdings Co., Ltd. (000640.KS)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Jae-Hun Jung | CEO, VP & Inside Director | -- | -- | 1971 |
| Mr. Seung Hyun Ko | Executive Director, CFO & Head of Management Support Office | -- | -- | -- |
| Mr. Min-Woo Jo | Executive Director & Head of Management Planning Office | -- | -- | -- |
Dong-A Socio Holdings Co., Ltd.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
Description
Dong-A Socio Holdings Co., Ltd. engages in the pharmaceutical business in South Korea and internationally. It develops DA-1241 for the treatment of type 2 diabetes and non-alcoholic steatohepatitis; DA-1726, an oxyntomodulin analogue to treat obesity; DA-1229, a dipeptidyl peptidase-4 inhibitor class treatment for type 2 diabetes; DA-8010, a muscarinic M3 receptor antagonist for the treatment of overactive bladder; DMB-3115, a biosimilar of Stelara and an inflammatory disease treatment; DA-3880 to treat anemia; STP0404, an HIV-1 treatment drug; and STP1002, an anti-cancer drug. The company also provides healthcare solutions to customers in Bacchus, over-the-counter, consumer healthcare, and derma business areas; CDMO services; imaging equipment and ENT workstation products; mineral water under the Cheonnyeonsu brand name; and IT and construction services. In addition, it produces glass bottles, PET, and corrugated cardboard boxes; engages in the foundry equipment, logistics, and food and beverage businesses. The company was founded in 1932 and is headquartered in Seoul, South Korea.
Corporate Governance
Recent Events
- Dec 27, 2023Ex-Dividend Date